Portfolio companies news

28 May 2014

Tragara’s TG02 is Highly Active in CLL Cells Derived from Patients

TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy.

14 May 2014

Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the Revolixys™ Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its first quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results will be held, May 14, 2014, at 8:30 a.m. EDT.

13 May 2014

Marinus braves a cooling biotech IPO market with a $63M pitch

John Carroll, FierceBiotech

A bit more than a year after Domain and its colleagues at RusNano put up a $21 million C round, New Haven, CT-based Marinus Pharmaceuticals is hoping to catch the wave of biotech IPOs. Marinus has filed an S-1 outlining plans to raise $63 million on Nasdaq, even as the latest round of new biotech offerings has seen several painful stumbles out of the gate.

23 April 2014

Advances in Presbyopia Correction

Roger F. Steinert, MD / Medscape

Hello. I'm Dr. Roger Steinert, Chair of Ophthalmology and Director of the Gavin Herbert Eye Institute at the University of California, Irvine. I just returned from the World Ophthalmology Congress, held this year in Tokyo, Japan, and had the opportunity to participate in several sessions on presbyopia treatments with intracorneal inlays.

02 April 2014

Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the planned “all comers” percutaneous coronary intervention (PCI) patient population described in the trial protocol. 

27 March 2014

Syndax Files Registration Statement for Proposed Initial Public Offering

Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined.

20 March 2014

ECOG-ACRIN Opens Phase III Trial of Syndax’s Entinostat in Advanced Breast Cancer

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112.

19 March 2014

FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration (FDA) has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program. The FDA's Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions that fill an unmet medical need, with the overall goal of getting new drugs to patients earlier. 

12 March 2014

Regado Biosciences announces year-end 2013 financial results and corporate highlights

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. 

17 February 2014

Hydrogel corneal inlay improves near, intermediate, distance vision at 3 months

Matt Hasson / Healio Ophthalmology

A hydrogel corneal inlay improved near, intermediate and distance vision, regardless of preoperative refractive error, according to a study presented at Hawaiian Eye 2014.